In the dynamic and strictly regulated world of pharmaceuticals, field medical representatives face colossal pressure. They must not only possess intricate knowledge of complex drug data and the latest clinical research but also be adept at building effective, personalized dialogues with demanding healthcare professionals (HCPs) – all within tight timeframes and under the strictest compliance. On May 13, 2025, ACTO, a leader in intelligent field excellence (IFE) platforms for the life sciences industry and a long-standing Veeva Technology Partner, made a resounding announcement promising to equip these "frontline warriors" with a true AI super-brain. This refers to the launch of the next generation of their renowned AI assistant – ACTO LAICA™ (Life Sciences AI Conversational Assistant).
This announcement, made in conjunction with the Veeva Commercial Summit, signifies not just an update, but a quantum leap in the platforms capabilities. The new generation of LAICA™ promises a "deeper level of personalization and intelligence," enabling field teams to prepare for HCP meetings more efficiently and engage with them with greater confidence and relevance. Imagine an assistant that not only provides information but also anticipates a doctors needs, suggests the most suitable arguments and data from approved sources (e.g., from Veeva Vault PromoMats and MedComms, thanks to tight integration), all in real-time, perhaps even during the visit itself.
ACTO has already established itself with generative AI-based products like LAICA RepAssist™ (a voice-enabled conversational assistant for instant answers based on approved content) and TalkTRx™ (a tool providing key talking points and best practice tips for using materials during HCP interactions). The enhanced ACTO LAICA™ will build upon these developments, offering even more refined customization for each user and every specific situation. This means a medical representative can receive not general recommendations, but advice maximally adapted to a specific doctors profile, their interests, previous interaction history, and current clinical data. Such a level of personalization is critically important for building trusting relationships and effectively communicating the value of medications.
ACTO emphasizes that its AI solutions are created to enhance the "human touch" in communications, not replace it. By providing representatives with instant access to verified information and intelligent prompts, LAICA™ frees them from the need to memorize vast amounts of data and allows them to focus on building quality dialogue and understanding the doctors needs. This is particularly relevant given the ever-increasing flow of medical information and the shrinking time doctors can allocate to representatives. ACTOs participation in the Veeva AI Partner Program also ensures that the solutions will be seamlessly integrated into the familiar workflows of teams using the Veeva ecosystem and will meet high industry standards for security and compliance. The announcement of the new generation of LAICA™ is another step towards a future where AI becomes an indispensable partner for life sciences professionals, helping them work smarter, faster, and more effectively.